

UNITED STATES PATENT AND TRADEMARK OFFICE



APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/972,402	10/05/2001	Mark A. Gallop	033053-034	3864
21839 7	590 08/20/2003			
BURNS DOANE SWECKER & MATHIS L L P			EXAMINER	
POST OFFICE ALEXANDRIA	BOX 1404 A, VA 22313-1404		MELLER, MICHAEL V	
			ART UNIT	PAPER NUMBER
			1654	
			DATE MAILED: 08/20/2003	7

Please find below and/or attached an Office communication concerning this application or proceeding.

→		Application No.	Applicant(s)			
- Office Action Summary		09/972,402	GALLOP ET AL.			
		Examiner	Art Unit			
		Michael V. Meller	1654			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status						
1)⊠	Responsive to communication(s) filed on 20 J	<u>une 2003</u> .				
2a) <u></u> □	This action is FINAL . 2b)⊠ Thi	s action is non-final.				
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213. Disposition of Claims						
4) Claim(s) 1-42 is/are pending in the application.						
4a) Of the above claim(s) 1 and 3-42 is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6)⊠ Claim(s) <u>2</u> is/are rejected.						
7)	Claim(s) is/are objected to.					
8) Claim(s) are subject to restriction and/or election requirement.						
Application Papers						
9) The specification is objected to by the Examiner.						
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
11)☐ The proposed drawing correction filed on is: a)☐ approved b)☐ disapproved by the Examiner.						
If approved, corrected drawings are required in reply to this Office action.						
12) The oath or declaration is objected to by the Examiner.						
Priority under 35 U.S.C. §§ 119 and 120						
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a) All b) Some * c) None of:						
1. Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No						
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).						
 a) ☐ The translation of the foreign language provisional application has been received. 15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121. 						
Attachment(s)						
2) Notice	of References Cited (PTO-892) of Draftsperson's Patent Drawing Review (PTO-948) ation Disclosure Statement(s) (PTO-1449) Paper No(s)	5) 🔲 Notice of Informal F	(PTO-413) Paper No(s) Patent Application (PTO-152)			
.S. Patent and Tra	demark Office					

Art Unit: 1654

DETAILED ACTION

Election/Restrictions

The invention is drawn to a compound having a formula (I). The compounds vary distinctly in their structures. Thus, an individual compound search is required of each individual compound (species) which cannot even be determined in this case.

Therefore, as part of the election/restriction since applicant elected Group II and the specific compound in Figure 10, compound (4), the examination of this application will be limited to this compound.

Applicant's election with traverse of Group II, claim 2 and the compound in figure 10, compound 4 in Paper No. 8 is acknowledged. The traversal is on the ground(s) that the search of the inventions will overlap since the inventions are so closely related to one another. This is not found persuasive because the inventions are not closely related to each other at all. Applicant is reminded of the extensive literature search for each compound and method which is not co-extensive. Each of the methods have different modes of operation and effects from one another and the compounds are structurally distinct from one another which is on the record. Each of the compounds is structurally distinct from one another and each require a different search. The independent claims claim extremely broad structures which are impossible to carry out a reasonable search on. Thus, the examination of the subject matter herein is limited to the compound in figure 10 compound 4 as elected by applicant.

Claims 1 and 3-42 are withdrawn from further consideration as being drawn to non-elected subject matter.

The requirement is still deemed proper and is therefore made FINAL.

Claim Rejections - 35 USC § 101

35 U.S.C. 101 reads as follows:

Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.

The claimed invention lacks patentable utility since there is nothing in the claim to indicate that the compound has been isolated.

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claim 2 is rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in

Application/Control Number: 09/972,402

Art Unit: 1654

the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

Applicant has only described the particular compound in figure 10, compound 4. Applicant has not shown that they were in possession of any and all compounds encompassed by claim 2. The specification only describes possession of this particular compound. Without any showing that any other compound encompassed by claim 2 applicant was in possession of at the time the invention was made, the invention is properly rejected under this section.

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claim 2 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 2 is written in such confusing language. For example, what is meant by "a drug having therapeutic or prophylactic activity when delivered to the systemic circulation of said animal". What animal ? What activity is being contemplated ? This is simply not clear. Further how can "T" be a moiety selected to permit the compound of formula I to be translocated across the intestinal wall of an animal if "T" is part of the compound of formula I. It simply is not clear what these symbols (D,Y and T) stand for in the claim.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michael V. Meller whose telephone number is 703-308-4230. The examiner can normally be reached on Monday thru Friday: 9:00am-5:30pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Brenda Brumback can be reached on 703-306-3220. The fax phone numbers for the organization where this application or proceeding is assigned are 703-872-9306 for regular communications and 703-872-9306 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

Michael V. Meller Primary Examiner Art Unit 1654

MVM August 12, 2003